Results 1 to 10 of about 53,193 (289)

First Report of RET Fusion‐Positive Lung Adenocarcinoma With Miliary Intrapulmonary Metastases Responsive to Selpercatinib: A Case Report [PDF]

Clinical Case Reports
Lung cancer presenting with miliary lung metastases on chest computed tomography is associated with poor prognosis. Recent studies indicate that non‐small cell lung cancer harboring driver gene mutations, including rearranged during transfection (RET ...
Soichi Iwanaka, Tadashi Nishimura, Hajime Fujimoto, Daichi Morita, Hitoshi Kuru, Yasumasa Sakakura, Corina N. D'Alessandro‐Gabazza, Taro Yasuma, Esteban C. Gabazza, Masahiro Naito, Hidenori Ibata, Tetsu Kobayashi   +11 more
doaj   +4 more sources

Highly sensitive droplet digital PCR for detection of RET fusion in papillary thyroid cancer [PDF]

BMC Cancer, 2023
Background Thyroid cancer is the most frequent malignancy of the endocrine system, of which papillary thyroid cancer (PTC) is the predominant form with a rapid increasing incidence worldwide.
Mengke Chen, Junyu Xue, Ye Sang, Wenting Jiang, Weiman He, Shubin Hong, Weiming Lv, Haipeng Xiao, Rengyun Liu   +8 more
doaj   +2 more sources

Case Report: Complete pathologic response to neoadjuvant selpercatinib in a patient with resectable early-stage RET fusion-positive non-small cell lung cancer [PDF]

Frontiers in Oncology, 2023
The LIBRETTO-001 trial demonstrated the activity of the selective rearrangement during transfection (RET) inhibitor selpercatinib in advanced RET fusion-positive non-small cell lung cancer (NSCLC) and resulted in the drug’s approval for this indication ...
Jonathan W. Goldman, Lynette M. Sholl, Sanja Dacic, Michael C. Fishbein, Yonina R. Murciano-Goroff, Ravi Rajaram, Sylwia Szymczak, Anna M. Szpurka, Bo H. Chao, Alexander Drilon, Alexander Drilon   +10 more
doaj   +2 more sources

The fusion characteristics of RET fusion in pan-cancer among the Chinese population: A comprehensive genomic analysis [PDF]

Translational Oncology
Background: RET fusions are significant oncogenic drivers, resulting from chromosomal rearrangements of the RET proto-oncogene with various partner genes.
Yi Zhao, Ruo Du, Mingcong Chen, Zhiwei Chen   +3 more
doaj   +2 more sources

Expert consensus on the diagnosis and treatment of RET gene fusion non‐small cell lung cancer in China [PDF]

Thoracic Cancer, 2023
The rearranged during transfection (RET) gene is one of the receptor tyrosine kinases and cell‐surface molecules responsible for transmitting signals that regulate cell growth and differentiation.
Xingxiang Pu, Chunwei Xu, Qian Wang, Wenxian Wang, Fang Wu, Xiuyu Cai, Zhengbo Song, Jinpu Yu, Wenzhao Zhong, Zhijie Wang, Yongchang Zhang, Jingjing Liu, Shirong Zhang, Anwen Liu, Wen Li, Ping Zhan, Hongbing Liu, Tangfeng Lv, Liyun Miao, Lingfeng Min, Gen Lin, Long Huang, Jingping Yuan, Zhansheng Jiang, Chuangzhou Rao, Dongqing Lv, Zongyang Yu, Xiaoyan Li, Chuanhao Tang, Chengzhi Zhou, Junping Zhang, Hui Guo, Qian Chu, Rui Meng, Xuewen Liu, Jingxun Wu, Jin Zhou, Zhengfei Zhu, Weiwei Pan, Fei Pang, Jintao Huang, Kai Wang, Fan Wu, Tingting Shen, Shirui Zou, Bingwei Xu, Liping Wang, Youcai Zhu, Xinqing Lin, Jing Cai, Ling Xu, Jisheng Li, Xiaodong Jiao, Kainan Li, Huijing Feng, Lin Wang, Yingying Du, Wang Yao, Xuefei Shi, Xiaomin Niu, Dongmei Yuan, Yanwen Yao, Jing Kang, Jiatao Zhang, Chao Zhang, Jianfei Fu, Jianhui Huang, Yinbin Zhang, Pingli Sun, Hong Wang, Mingxiang Ye, Dong Wang, Zhaofeng Wang, Yue Hao, Zhen Wang, Bing Wan, Donglai Lv, Gang Lan, Shengjie Yang, Lin Shi, Yina Wang, Bihui Li, Zhang Zhang, Zhongwu Li, Yuan Li, Zhefeng Liu, Nong Yang, Huijuan Wang, Wenbin Huang, Zhuan Hong, Guansong Wang, Jiandong Wang, Meiyu Fang, Yong Fang, Xixu Zhu, Yi Shen, Yiping Zhang, Shenglin Ma, Yong Song, Yuanzhi Lu, Wenfeng Fang, Ziming Li, Lin Wu   +102 more
doaj   +2 more sources

Case Report: Complete pathologic response to neoadjuvant immunotherapy-chemotherapy in a patient with RET fusion-positive non-small cell lung cancer [PDF]

Frontiers in Oncology
RET fusions are rare, and occur in 1%-2% of all non-small cell lung cancer (NSCLC) patients. While neoadjuvant immunotherapy-chemotherapy has demonstrated significant benefit for resectable NSCLC, data remain limited for oncogene-positive NSCLC ...
Yan Wang, Yan Zhang, Chenlei Cai, Xinyu Liu, Shengxiang Ren, Songwen Zhou   +5 more
doaj   +2 more sources

Primary Resistance to RET Inhibition in a RET Fusion-Positive Pancreatic Neuroendocrine Carcinoma. [PDF]

Oncologist
Abstract We present a 54-year-old White male with a diagnosis of stage IV pancreatic neuroendocrine carcinoma. Next-generation sequencing of the tumor/blood identified a complex tumor genome, which included a rearranged during transfection (RET) gene fusion.
McKinley BJ, Coston TW, Starr JS.
europepmc   +3 more sources

TRIM24/RET Fusion Protein [PDF]

, 2020
National Cancer Institute
openalex   +2 more sources

Case Report: Successful late-line pralsetinib treatment in an ALK-rearranged lung adenocarcinoma patient with KIF5B-RET fusion resistant to alectinib [PDF]

Frontiers in Genetics
Anaplastic lymphoma kinase (ALK) fusion, an oncogenic driver alteration, accounts for 5%–6% of non-small cell lung cancer (NSCLC) patients. ALK tyrosine kinase inhibitors (TKIs) provide significant clinical benefit in advanced ALK-rearranged NSCLC ...
Feng Jin, Chenyang Wang, Fang Yang, Shubin Wang, Fen Wang   +4 more
doaj   +2 more sources

RET Inhibitors in RET Fusion-Positive Lung Cancers: Past, Present, and Future. [PDF]

Drugs
While activating RET fusions are identified in various cancers, lung cancer represents the most common RET fusion-positive tumor. The clinical drug development of RET inhibitors in RET fusion-positive lung cancers naturally began after RET fusions were first identified in patient tumor samples in 2011, and thereafter paralleled drug development in RET ...
Chen MF, Repetto M, Wilhelm C, Drilon A.
europepmc   +3 more sources